Selected research
Industry Research
APOL1 Mediated Kidney Disease Industry Research Report 2026
Market perspective
The global APOL1 Mediated Kidney Disease market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the APOL1 Mediated Kidney Disease market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the APOL1 Mediated Kidney Disease market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the APOL1 Mediated Kidney Disease market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of APOL1 Mediated Kidney Disease include Teva Pharmaceuticals, Novartis, ZyVersa Therapeutics, Vertex Pharmaceuticals, Travere Therapeutics, Ionis Pharmaceuticals, GlaxoSmithKline and ChemoCentryx, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global APOL1 Mediated Kidney Disease market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to APOL1 Mediated Kidney Disease.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
APOL1 Mediated Kidney Disease Market by Company
Teva Pharmaceuticals
Novartis
ZyVersa Therapeutics
Vertex Pharmaceuticals
Travere Therapeutics
Ionis Pharmaceuticals
GlaxoSmithKline
ChemoCentryx
APOL1 Mediated Kidney Disease Segment by Type
Small Molecule
Gene Modification
Nucleic Acid Therapies
Others
APOL1 Mediated Kidney Disease Segment by Application
Chronic Kidney Disease
End Stage Kidney Disease
APOL1 Mediated Kidney Disease Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global APOL1 Mediated Kidney Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of APOL1 Mediated Kidney Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of APOL1 Mediated Kidney Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of APOL1 Mediated Kidney Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Small Molecule
- Gene Modification
- Nucleic Acid Therapies
- Others
Applications
- Chronic Kidney Disease
- End Stage Kidney Disease
Companies covered
- Teva Pharmaceuticals
- Novartis
- ZyVersa Therapeutics
- Vertex Pharmaceuticals
- Travere Therapeutics
- Ionis Pharmaceuticals
- GlaxoSmithKline
- ChemoCentryx
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 APOL1 Mediated Kidney Disease by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Small Molecule
- 2.2.3 Gene Modification
- 2.2.4 Nucleic Acid Therapies
- 2.2.5 Others
- 2.3 APOL1 Mediated Kidney Disease by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Chronic Kidney Disease
- 2.3.3 End Stage Kidney Disease
- 2.4 Assumptions and Limitations
3 APOL1 Mediated Kidney Disease Breakdown Data by Type
- 3.1 Global APOL1 Mediated Kidney Disease Historic Market Size by Type (2021-2026)
- 3.2 Global APOL1 Mediated Kidney Disease Forecasted Market Size by Type (2027-2032)
4 APOL1 Mediated Kidney Disease Breakdown Data by Application
- 4.1 Global APOL1 Mediated Kidney Disease Historic Market Size by Application (2021-2026)
- 4.2 Global APOL1 Mediated Kidney Disease Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global APOL1 Mediated Kidney Disease Market Perspective (2021-2032)
- 5.2 Global APOL1 Mediated Kidney Disease Growth Trends by Region
- 5.2.1 Global APOL1 Mediated Kidney Disease Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 APOL1 Mediated Kidney Disease Historic Market Size by Region (2021-2026)
- 5.2.3 APOL1 Mediated Kidney Disease Forecasted Market Size by Region (2027-2032)
- 5.3 APOL1 Mediated Kidney Disease Market Dynamics
- 5.3.1 APOL1 Mediated Kidney Disease Industry Trends
- 5.3.2 APOL1 Mediated Kidney Disease Market Drivers
- 5.3.3 APOL1 Mediated Kidney Disease Market Challenges
- 5.3.4 APOL1 Mediated Kidney Disease Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top APOL1 Mediated Kidney Disease Players by Revenue
- 6.1.1 Global Top APOL1 Mediated Kidney Disease Players by Revenue (2021-2026)
- 6.1.2 Global APOL1 Mediated Kidney Disease Revenue Market Share by Players (2021-2026)
- 6.2 Global APOL1 Mediated Kidney Disease Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of APOL1 Mediated Kidney Disease Head Office and Area Served
- 6.4 Global APOL1 Mediated Kidney Disease Players, Product Type & Application
- 6.5 Global APOL1 Mediated Kidney Disease Manufacturers Established Date
- 6.6 Global APOL1 Mediated Kidney Disease Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America APOL1 Mediated Kidney Disease Market Size (2021-2032)
- 7.2 North America APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America APOL1 Mediated Kidney Disease Market Size by Country (2021-2026)
- 7.4 North America APOL1 Mediated Kidney Disease Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe APOL1 Mediated Kidney Disease Market Size (2021-2032)
- 8.2 Europe APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe APOL1 Mediated Kidney Disease Market Size by Country (2021-2026)
- 8.4 Europe APOL1 Mediated Kidney Disease Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific APOL1 Mediated Kidney Disease Market Size (2021-2032)
- 9.2 Asia-Pacific APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Country (2021-2026)
- 9.4 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America APOL1 Mediated Kidney Disease Market Size (2021-2032)
- 10.2 South America APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America APOL1 Mediated Kidney Disease Market Size by Country (2021-2026)
- 10.4 South America APOL1 Mediated Kidney Disease Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa APOL1 Mediated Kidney Disease Market Size (2021-2032)
- 11.2 Middle East & Africa APOL1 Mediated Kidney Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2021-2026)
- 11.4 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Teva Pharmaceuticals
- 12.1.1 Teva Pharmaceuticals Company Information
- 12.1.2 Teva Pharmaceuticals Business Overview
- 12.1.3 Teva Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2021-2026)
- 12.1.4 Teva Pharmaceuticals APOL1 Mediated Kidney Disease Product Portfolio
- 12.1.5 Teva Pharmaceuticals Recent Developments
- 12.2 Novartis
- 12.2.1 Novartis Company Information
- 12.2.2 Novartis Business Overview
- 12.2.3 Novartis Revenue in APOL1 Mediated Kidney Disease Business (2021-2026)
- 12.2.4 Novartis APOL1 Mediated Kidney Disease Product Portfolio
- 12.2.5 Novartis Recent Developments
- 12.3 ZyVersa Therapeutics
- 12.3.1 ZyVersa Therapeutics Company Information
- 12.3.2 ZyVersa Therapeutics Business Overview
- 12.3.3 ZyVersa Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2021-2026)
- 12.3.4 ZyVersa Therapeutics APOL1 Mediated Kidney Disease Product Portfolio
- 12.3.5 ZyVersa Therapeutics Recent Developments
- 12.4 Vertex Pharmaceuticals
- 12.4.1 Vertex Pharmaceuticals Company Information
- 12.4.2 Vertex Pharmaceuticals Business Overview
- 12.4.3 Vertex Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2021-2026)
- 12.4.4 Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Product Portfolio
- 12.4.5 Vertex Pharmaceuticals Recent Developments
- 12.5 Travere Therapeutics
- 12.5.1 Travere Therapeutics Company Information
- 12.5.2 Travere Therapeutics Business Overview
- 12.5.3 Travere Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2021-2026)
- 12.5.4 Travere Therapeutics APOL1 Mediated Kidney Disease Product Portfolio
- 12.5.5 Travere Therapeutics Recent Developments
- 12.6 Ionis Pharmaceuticals
- 12.6.1 Ionis Pharmaceuticals Company Information
- 12.6.2 Ionis Pharmaceuticals Business Overview
- 12.6.3 Ionis Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2021-2026)
- 12.6.4 Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Product Portfolio
- 12.6.5 Ionis Pharmaceuticals Recent Developments
- 12.7 GlaxoSmithKline
- 12.7.1 GlaxoSmithKline Company Information
- 12.7.2 GlaxoSmithKline Business Overview
- 12.7.3 GlaxoSmithKline Revenue in APOL1 Mediated Kidney Disease Business (2021-2026)
- 12.7.4 GlaxoSmithKline APOL1 Mediated Kidney Disease Product Portfolio
- 12.7.5 GlaxoSmithKline Recent Developments
- 12.8 ChemoCentryx
- 12.8.1 ChemoCentryx Company Information
- 12.8.2 ChemoCentryx Business Overview
- 12.8.3 ChemoCentryx Revenue in APOL1 Mediated Kidney Disease Business (2021-2026)
- 12.8.4 ChemoCentryx APOL1 Mediated Kidney Disease Product Portfolio
- 12.8.5 ChemoCentryx Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst